Uveal melanoma is a rare eye cancer. When it is confined to the eye, it can be treated with surgery and radiation therapy. But when it spreads, it is more difficult to treat successfully. The purpose of this study is to evaluate the safety and effectiveness of vorinostat for treating metastatic uveal melanoma.
Vorinostat is approved for treating a form of lymphoma, but its use for uveal melanoma is considered investigational. It is a drug called a histone deacetylase inhibitor, which prevents cancer cells from reproducing by interfering with certain signaling pathways. Vorinostat is a capsule that is taken orally (by mouth).